As of Oct 21
| -0.20 / -2.08%|
The 7 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 16.00, with a high estimate of 20.00 and a low estimate of 6.75. The median estimate represents a +70.21% increase from the last price of 9.40.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.